1178583-19-1

Basic information

• Product Name: 5‐hydroxy‐8‐methoxy‐2-phenyl-7‐(4‐(pyrrolidin‐1‐yl)butoxy)‐4H‐chromen‐4‐one
• Synonyms: 5‐hydroxy‐8‐methoxy‐2-phenyl-7‐(4‐(pyrrolidin‐1‐yl)butoxy)‐4H‐chromen‐4‐one
• CAS NO: 1178583-19-1
• Molecular Weight: 409.482
• Mol File: 1178583-19-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5‐hydroxy‐8‐methoxy‐2-phenyl-7‐(4‐(pyrrolidin‐1‐yl)butoxy)‐4H‐chromen‐4‐one(CAS DataBase Reference)
• NIST Chemistry Reference: 5‐hydroxy‐8‐methoxy‐2-phenyl-7‐(4‐(pyrrolidin‐1‐yl)butoxy)‐4H‐chromen‐4‐one(1178583-19-1)
• EPA Substance Registry System: 5‐hydroxy‐8‐methoxy‐2-phenyl-7‐(4‐(pyrrolidin‐1‐yl)butoxy)‐4H‐chromen‐4‐one(1178583-19-1)

Safety Data

• Hazardous Substances Data: 1178583-19-1(Hazardous Substances Data)

Upstream product

• 123-75-1 pyrrolidine 
• 632-85-9 wogonin 
• 102-92-1 cinnamoyl chloride 
• 20032-42-2 2,5-dimethoxyresorcinol 
• 6274-74-4 2,6-dibenzyloxy-1,4-dimethoxybenzene 
• 6625-45-2 2,6-bis-benzyloxy-[1,4]benzoquinone 
• 55020-64-9 1,2,3-tris-benzyloxybenzene 
• 87-66-1 2-hydroxyresorcinol 

Relevant articles and documents

Synthesis, evaluation and quantitative structure–activity relationship (QSAR) analysis of Wogonin derivatives as cytotoxic agents

A novel series of 49 wogonin derivatives were synthesized by introducing group at 7-, 8- or B ring of wogonin. The cytotoxic activities against HepG2, A549 and BCG-823 cancer cell lines were also investigated in vitro. Several of them showed obvious cytotoxic activities and compound 3h possessed the highest potency against HepG2, A549, and BCG-823 with IC50 values of 1.07 μM, 1.74 μM and 0.98 μM, respectively. A quantitative structure-activity relationship (QSAR) study of these synthetic derivatives as well as wogonin indicated that high solubility and low octanol/water partition coefficient are favorable, and excessive electrostatic properties and refractivity are unfavorable for the cytotoxic activities of these wogonin derivatives. These findings and results provide a base for further investigations.